i-PRF Perfusion Trial for Moderate to Severe Intrauterine Adhesions
Summary
NIH's ClinicalTrials.gov registered a new prospective randomized controlled study (NCT07536971) evaluating the efficacy and safety of intrauterine i-PRF (injectable platelet-rich fibrin) perfusion in women with moderate to severe intrauterine adhesions after hysteroscopic adhesiolysis. The trial will compare i-PRF intrauterine perfusion against sodium hyaluronate intrauterine treatment, assessing endometrial regeneration and reproductive outcomes. The anticipated study start date is April 17, 2026.
What changed
A new clinical trial registration on ClinicalTrials.gov describes a prospective randomized controlled study evaluating i-PRF intrauterine perfusion versus sodium hyaluronate treatment in women with moderate to severe intrauterine adhesions following hysteroscopic adhesiolysis. The trial will assess endometrial regeneration, re-adhesion rates, and reproductive outcomes.
Healthcare providers, clinical investigators, and patients involved in reproductive health research may encounter this trial as a reference point for emerging treatment approaches. The study registration provides transparency on ongoing research but does not create compliance obligations for regulated entities.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Clinical Study of i-PRF Intrauterine Perfusion for Endometrial Regeneration and Repair in Moderate to Severe Intrauterine Adhesions
N/A NCT07536971 Kind: NA Apr 17, 2026
Abstract
Intrauterine adhesions (IUA) caused by endometrial basal layer injury can lead to reduced menstrual flow, infertility, recurrent pregnancy loss, and poor reproductive outcomes. Hysteroscopic adhesiolysis with uterine cavity reconstruction is the standard treatment, but women with moderate to severe IUA still have high rates of re-adhesion and unsatisfactory endometrial repair after surgery.
Injectable platelet-rich fibrin (i-PRF) is an autologous blood-derived biologic material that can be prepared at the bedside. Compared with conventional platelet-rich plasma, i-PRF may provide a more sustained release of growth factors and form a fibrin scaffold after intrauterine administration, which may help protect the wound surface, support endometrial regeneration, improve blood perfusion, and reduce postoperative re-adhesion.
This prospective randomized controlled study will evaluate the efficacy and safety of intrauterine i-PRF perfusion in women with moderate to severe IUA after hysteroscopic adhesiolysis. Participants will be assigned to receive either i-PRF intrauterine perfusion or sodium hyaluronate intrauterine treatment after surgery. The study will compare postoperative uterine cavity recovery, endometrial thickness and blood flow, clinical pregnancy outcomes, and safety events. The goal is to determine whether i-PRF can improve endometrial regeneration and reproductive outcomes and provide evidence for an optimized postoperative treatment strategy for moderate to seve...
Conditions: Intrauterine Adhesions
Interventions: Injectable Platelet-Rich Fibrin, Sodium Hyaluronate
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.